Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.
作者信息
Ortiz Alberto, Fernandez-Fernandez Beatriz
机构信息
Nephrology Department, Fundación Jimenez Díaz Health Research Institute, Madrid, Spain.
Department of Medicine, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
出版信息
Clin J Am Soc Nephrol. 2021 Dec;16(12):1775-1778. doi: 10.2215/CJN.13601021. Epub 2021 Dec 1.
Abstract
摘要
相似文献
1
Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.阿曲生坦：将内皮素A受体拮抗剂纳入糖尿病肾病当前治疗模式的艰巨任务。
Clin J Am Soc Nephrol. 2021 Dec;16(12):1775-1778. doi: 10.2215/CJN.13601021. Epub 2021 Dec 1.
2
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.在使用内皮素受体拮抗剂阿曲生坦治疗期间的利尿药物与液体潴留生物标志物的变化
Diabetes Obes Metab. 2023 Aug;25(8):2419-2422. doi: 10.1111/dom.15110. Epub 2023 May 8.
3
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.内皮素受体拮抗剂在 2 型糖尿病肾病中的疗效和安全性：系统评价和随机对照试验的荟萃分析。
Diabet Med. 2021 Jan;38(1):e14411. doi: 10.1111/dme.14411. Epub 2020 Oct 9.
4
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.《阿托伐他汀治疗糖尿病肾病的研究（SONAR）：一项针对糖尿病肾病的临床试验设计》的研究背景和方案
Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9.
5
Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy.阿曲生坦通过恢复糖尿病肾病中肾小球内皮糖萼屏障来减少蛋白尿。
Diabetes. 2016 Aug;65(8):2429-39. doi: 10.2337/db15-1413. Epub 2016 Mar 25.
6
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.依前列醇受体拮抗剂治疗时蛋白尿的早期反应和长期肾脏保护：SONAR 试验的预先指定分析。
J Am Soc Nephrol. 2021 Nov;32(11):2900-2911. doi: 10.1681/ASN.2021030391. Epub 2021 Sep 22.
7
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.通过评估蛋白尿和体重的暴露-反应关系来确定阿曲生坦的最佳剂量。
Diabetes Obes Metab. 2018 Aug;20(8):2019-2022. doi: 10.1111/dom.13312. Epub 2018 May 1.
8
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.内皮素拮抗剂阿曲生坦可降低2型糖尿病肾病患者的残余蛋白尿。
J Am Soc Nephrol. 2014 May;25(5):1083-93. doi: 10.1681/ASN.2013080830. Epub 2014 Apr 10.
9
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.阿曲生坦对2型糖尿病肾病患者尿液代谢物的影响。
Diabetes Obes Metab. 2017 May;19(5):749-753. doi: 10.1111/dom.12864. Epub 2017 Feb 22.
10
Atrasentan for the treatment of diabetic nephropathy.阿曲生坦用于治疗糖尿病肾病。
Expert Opin Investig Drugs. 2017 Jun;26(6):741-750. doi: 10.1080/13543784.2017.1325872.
引用本文的文献
1
Potential New Treatments for Chronic Kidney Diseases: A Concise Review.慢性肾脏病的潜在新疗法：简要综述
Curr Pharm Des. 2025 Feb 6. doi: 10.2174/0113816128360091250117040009.
2
New insights in the treatment of DKD: recent advances and future prospects.糖尿病肾病治疗的新见解：近期进展与未来展望。
BMC Nephrol. 2025 Feb 11;26(1):72. doi: 10.1186/s12882-025-03953-3.
3
The Anti-Inflammatory and Curative Exponent of Probiotics: A Comprehensive and Authentic Ingredient for the Sustained Functioning of Major Human Organs.益生菌的抗炎和治疗功效：主要人体器官持续功能的综合和纯正成分。
Nutrients. 2024 Feb 16;16(4):546. doi: 10.3390/nu16040546.
4
Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis.慢性肾脏病透析患者腹膜损伤中免疫反应的新方面。
Int J Mol Sci. 2023 Mar 17;24(6):5763. doi: 10.3390/ijms24065763.
5
Novel strategies in nephrology: what to expect from the future?肾脏病学的新策略：未来可期？
Clin Kidney J. 2022 Sep 20;16(2):230-244. doi: 10.1093/ckj/sfac212. eCollection 2023 Feb.
6
Probiotics for kidney disease.用于肾脏疾病的益生菌。
Clin Kidney J. 2022 Feb 28;15(11):1981-1986. doi: 10.1093/ckj/sfac056. eCollection 2022 Nov.
Zotero 插件